PedAM
Pediatric Disease Annotations & Medicines
| Disease | hyperuricemia |
| Phenotype | C0010674|cystic fibrosis |
| Sentences | 1 |
| PubMedID- 22936895 | Although hyperuricemia was reported in patients with cystic fibrosis treated with pancreatic enzyme products,51 the most recent studies have found no significant association between the use of pancrelipase and hyperuricemia.32,41 fibrosing colonopathy, a serious complication of cystic fibrosis, can develop several months to several years after starting high-dose pert.52 generally, high doses of enzymes (eg, >75,000 units/meal for adults and >25,000 units/meal for children) are not recommended,7,50 nor are doses of lipase > 2500 units/kg/meal (10,000 units/kg/day).53 the cystic fibrosis foundation recommended in their consensus-based guidelines that dosages should be limited to 500–2500 lipase units/kg/meal, <10,000 lipase units/kg/day, or <4000 lipase units/g dietary fat/day.54 although the pathogenesis of fibrosing colonopathy is unknown, it is highly correlated with pancreatic enzyme dose, the clinical features of crohn’s disease, and ischemic bowel disease,52 and compounds present in enteric coatings designed to protect the enzymes against gastric acid.55 lee et al56 also proposed that local injury caused by proteases or immune activity may be responsible for the pathological changes in fibrosing colonopathy. |
Page: 1